Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inmune Bio, Inc.INMB · Entity 7094 | Director · President and CEO · 10% owner | December 05, 2024 | December 09, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inmune Bio, Inc.
Report date December 05, 2024 · Filed December 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.05 · Expires 2034-12-04 | Direct | 226,000 |
Reported balance
After 2024-12-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-12-05 · Grant · Acquired 226,000 · Balance 226,000 F1: Granted pursuant to the 2021 Stock Incentive Plan. The option will become 100% vested and exercisable on December 5, 2026, the two-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted pursuant to the 2021 Stock Incentive Plan. The option will become 100% vested and exercisable on December 5, 2026, the two-year anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 05, 2024 Filed Dec 9, 2024 21:00 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantOption (right to buy) · Derivative | 226,000 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0001213900-24-106918 · ownership.xml · derivative · entry 1 Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,000 Underlying: Common Stock · 226,000 shares Expires 2034-12-04 F1 · derivative.exercise_date: Granted pursuant to the 2021 Stock Incentive Plan. The option will become 100% vested and exercisable on December 5, 2026, the two-year anniversary of the grant date. Read SEC document |
| September 12, 2024 Filed Sep 17, 2024 00:48 UTC | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock Warrants (right to buy) · Derivative | 15,380 | $0.13 Strike: $6.40 | $1,922.50 |
DisclosureSEC source: 0001213900-24-079121 · ownership.xml · derivative · entry 2 Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,380 Underlying: Common Stock · 15,380 shares Expires 2030-03-16 F1 · derivative.exercise_date: The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $6.50, for an aggregate purchase price of $13,000,000 pursuant to a securities purchase agreement dated September 12, 2024. The Warrants are exercisable on or after March 16, 2025 and will terminate on March 16, 2030 unless such termination is accelerated pursuant to the terms of the Warrants (the "Termination Date"), provided, however, in the event that the Warrant is held by Insiders and the Termination Date is during a period that such Insiders are subject to a blackout with respect to trading in the Company's common stock, such Insiders will have an additional 60 days from the termination of the blackout to exercise the Warrant. The exercise price the Warrants is $6.40 per share subject to adjustment as provided in the Warrant. Read SEC document |
| September 12, 2024 Filed Sep 17, 2024 00:48 UTC | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock | 15,380 | $6.38 | $98,047.50 |
DisclosureSEC source: 0001213900-24-079121 · ownership.xml · nonDerivative · entry 1 Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,554,106 Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 20:30 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantOption (right to buy) · Derivative | 37,882 | $0.00 Strike: $8.72 | $0.00 |
DisclosureSEC source: 0001213900-24-052113 · ownership.xml · derivative · entry 1 Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,882 Underlying: Common Stock · 37,882 shares Expires 2034-06-09 F1 · derivative.exercise_date: The option was granted pursuant to the INmune Bio Inc. 2021 Stock Incentive Plan. The option is 100% vested and exercisable as of the grant date. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:10 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantOption (right to buy) · Derivative | 160,000 | $0.00 Strike: $9.92 | $0.00 |
DisclosureSEC source: 0001213900-24-044315 · ownership.xml · derivative · entry 1 Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2034-05-13 F1 · derivative.exercise_date: Granted pursuant to the 2021 Stock Incentive Plan. One fourth (1/4) of the option will vest 12 months from the grant date and thereafter the remaining unvested option will become vested and exercisable on a monthly basis over three (3) years (1/36 per month) until the option is 100% vested which shall occur on the four-year anniversary of the grant date. Read SEC document |
| April 19, 2024 Filed Apr 23, 2024 21:55 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantCommon Stock Warrants (right to buy) · Derivative | 18,028 | $0.13 Strike: $9.15 | $2,253.50 |
DisclosureSEC source: 0001213900-24-035474 · ownership.xml · derivative · entry 2 Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,028 Underlying: Common Stock · 18,028 shares Expires not disclosed F1 · derivative.expiration_date: The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $152,246.46 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the "Termination Date") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant. Read SEC document |
| April 19, 2024 Filed Apr 23, 2024 21:55 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantCommon Stock | 18,028 | $8.32 | $149,992.96 |
DisclosureSEC source: 0001213900-24-035474 · ownership.xml · nonDerivative · entry 1 Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,538,726 F1 · shares: The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $152,246.46 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the "Termination Date") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant. Read SEC document |
| April 19, 2024 Filed Apr 24, 2024 18:08 UTC Amendment | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock Warrants (right to buy) · Derivative | 18,028 | $0.13 Strike: $9.15 | $2,253.50 |
DisclosureSEC source: 0001213900-24-035722 · ownership.xml · derivative · entry 2 Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,028 Underlying: Common Stock · 18,028 shares Expires not disclosed F1 · derivative.expiration_date: The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $152,246.46 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the "Termination Date") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant. Read SEC document |
| April 19, 2024 Filed Apr 24, 2024 18:08 UTC Amendment | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock | 18,028 | $8.32 | $149,992.96 |
DisclosureSEC source: 0001213900-24-035722 · ownership.xml · nonDerivative · entry 1 Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,538,726 F1 · shares: The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $152,246.46 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the "Termination Date") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:09 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantOption (right to buy) · Derivative | 160,000 | $0.00 Strike: $9.74 | $0.00 |
DisclosureSEC source: 0001213900-23-013286 · ownership.xml · derivative · entry 1 Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2033-02-15 F1 · derivative.exercise_date: Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date. Read SEC document |
| May 26, 2022 Filed May 31, 2022 10:10 UTC | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock | 6,300 | $6.41 | $40,383.00 |
DisclosureSEC source: 0001213900-22-030210 · ownership.xml · nonDerivative · entry 1 Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,520,698 F1 · price: Represents the average purchase price at a range of between $6.37 and $6.43 per share. Read SEC document |
| March 22, 2022 Filed Mar 23, 2022 20:33 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantCommon Stock | 23,724 | $8.43 | $199,993.32 |
DisclosureSEC source: 0001213900-22-014507 · ownership.xml · nonDerivative · entry 1 Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,514,398 F1 · price: The purchase price of the common stock being reported is the closing price per share immediately preceding the entering into of the binding agreement to issue the securities . These shares were purchased by the Reporting Person directly from Issuer. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:33 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantOption (right to buy) · Derivative | 130,000 | $0.00 Strike: $7.92 | $0.00 |
DisclosureSEC source: 0001213900-22-014507 · ownership.xml · derivative · entry 2 Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2032-03-20 F2 · derivative.exercise_date: Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date. Read SEC document |
| November 03, 2021 Filed Nov 4, 2021 20:00 UTC | Inmune Bio, Inc. INMB · Entity 7094 | SaleCommon Stock | 3,626 | $20.00 | $72,520.00 |
DisclosureSEC source: 0001213900-21-056737 · ownership.xml · nonDerivative · entry 1 Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,490,674 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 27, 2021 Filed Oct 29, 2021 20:03 UTC | Inmune Bio, Inc. INMB · Entity 7094 | SaleCommon Stock | 6,517 | $20.00 | $130,340.00 |
DisclosureSEC source: 0001213900-21-055422 · ownership.xml · nonDerivative · entry 1 Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,494,300 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 22, 2021 Filed Oct 26, 2021 20:31 UTC | Inmune Bio, Inc. INMB · Entity 7094 | SaleCommon Stock | 23,616 | $20.00 | $472,320.00 |
DisclosureSEC source: 0001213900-21-054644 · ownership.xml · nonDerivative · entry 1 Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,817 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 20:42 UTC | Inmune Bio, Inc. INMB · Entity 7094 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001213900-21-045373 · ownership.xml · derivative · entry 2 Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 30,000 shares Expires 2029-11-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options were exercised in a cash transaction by the Reporting Person under Rule 16(b)(3). The options were granted to the Reporting Person under the Company's 2019 Stock Incentive Plan. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 20:42 UTC | Inmune Bio, Inc. INMB · Entity 7094 | Exercise / conversionCommon Stock | 30,000 | $3.91 | $117,300.00 |
DisclosureSEC source: 0001213900-21-045373 · ownership.xml · nonDerivative · entry 1 Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,524,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These options were exercised in a cash transaction by the Reporting Person under Rule 16(b)(3). The options were granted to the Reporting Person under the Company's 2019 Stock Incentive Plan. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 20:06 UTC | Inmune Bio, Inc. INMB · Entity 7094 | SaleCommon Stock | 24,351 | $20.08 | $488,968.08 |
DisclosureSEC source: 0001213900-21-036352 · ownership.xml · nonDerivative · entry 2 Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,510,933 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $20.00 to $20.21, inclusive. The Reporting Person undertakes to provide to Inmune Bio, Inc., any security holder of Inmune Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above. Read SEC document |
| July 07, 2021 Filed Jul 9, 2021 20:06 UTC | Inmune Bio, Inc. INMB · Entity 7094 | SaleCommon Stock | 5,649 | $20.02 | $113,081.68 |
DisclosureSEC source: 0001213900-21-036352 · ownership.xml · nonDerivative · entry 1 Tesi Raymond Joseph · CIK 0001767280 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,535,284 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $20.00 to $20.04, inclusive. The Reporting Person undertakes to provide to Inmune Bio, Inc., any security holder of Inmune Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the range set forth above. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 22:00 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantOption · Derivative | 70,663 | $0.00 Strike: $17.49 | $0.00 |
DisclosureSEC source: 0001213900-21-034018 · ownership.xml · derivative · entry 1 Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,663 Underlying: Common Stock · 70,663 shares Expires 2031-06-22 F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc. F2 · derivative.exercise_date: Options granted pursuant to 2021 Stock Incentive Plan. Twenty-five percent of the Option will vest 12 months from the date of grant and thereafter the remaining unvested Option will become vested and exercisable pro rata on a monthly basis over three (3) years (1/36 per month) until the Option is 100% vested which shall occur on the four-year anniversary of the date of grant. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:34 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantOption · Derivative | 59,337 | $0.00 Strike: $24.82 | $0.00 |
DisclosureSEC source: 0001213900-21-003483 · ownership.xml · derivative · entry 1 Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,337 Underlying: Common Stock · 59,337 shares Expires 2031-01-18 F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc. F2 · derivative.exercise_date: Options granted pursuant to 2019 Stock Incentive Plan Twenty-five percent of the Option will vest 12 months from the date of grant and thereafter the remaining unvested Option will become vested and exercisable pro rata on a monthly basis over three (3) years (1/36 per month) until the Option is 100% vested which shall occur on the four-year anniversary of the date of grant. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 21:41 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantOption · Derivative | 300,000 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001213900-19-024971 · ownership.xml · derivative · entry 1 Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 300,000 shares Expires not disclosed F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc. F2 · derivative.exercise_date: Vests pro rata on a monthly basis over three years (1/36) such that the Option will be fully vested three years from the date of grant. F2 · derivative.expiration_date: Vests pro rata on a monthly basis over three years (1/36) such that the Option will be fully vested three years from the date of grant. Read SEC document |
| August 20, 2019 Filed Aug 21, 2019 20:33 UTC | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock | 1,000 | $6.03 | $6,030.80 |
DisclosureSEC source: 0001213900-19-016453 · ownership.xml · nonDerivative · entry 11 Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,540,933 F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 20, 2019 in eleven open market transactions. Read SEC document |
| August 20, 2019 Filed Aug 21, 2019 20:33 UTC | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock | 100 | $5.92 | $592.39 |
DisclosureSEC source: 0001213900-19-016453 · ownership.xml · nonDerivative · entry 10 Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,539,933 F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 20, 2019 in eleven open market transactions. Read SEC document |
| August 20, 2019 Filed Aug 21, 2019 20:33 UTC | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock | 100 | $5.96 | $596.00 |
DisclosureSEC source: 0001213900-19-016453 · ownership.xml · nonDerivative · entry 9 Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,539,833 F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 20, 2019 in eleven open market transactions. Read SEC document |
| August 20, 2019 Filed Aug 21, 2019 20:33 UTC | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock | 100 | $5.96 | $596.00 |
DisclosureSEC source: 0001213900-19-016453 · ownership.xml · nonDerivative · entry 8 Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,539,733 F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 20, 2019 in eleven open market transactions. Read SEC document |
| August 20, 2019 Filed Aug 21, 2019 20:33 UTC | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock | 100 | $5.96 | $596.00 |
DisclosureSEC source: 0001213900-19-016453 · ownership.xml · nonDerivative · entry 7 Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,539,633 F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 20, 2019 in eleven open market transactions. Read SEC document |
| August 20, 2019 Filed Aug 21, 2019 20:33 UTC | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock | 100 | $5.96 | $596.00 |
DisclosureSEC source: 0001213900-19-016453 · ownership.xml · nonDerivative · entry 6 Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,539,533 F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 20, 2019 in eleven open market transactions. Read SEC document |
| August 20, 2019 Filed Aug 21, 2019 20:33 UTC | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock | 100 | $5.96 | $596.00 |
DisclosureSEC source: 0001213900-19-016453 · ownership.xml · nonDerivative · entry 5 Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,539,433 F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 20, 2019 in eleven open market transactions. Read SEC document |
| August 20, 2019 Filed Aug 21, 2019 20:33 UTC | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock | 100 | $5.96 | $596.00 |
DisclosureSEC source: 0001213900-19-016453 · ownership.xml · nonDerivative · entry 4 Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,539,333 F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 20, 2019 in eleven open market transactions. Read SEC document |
| August 20, 2019 Filed Aug 21, 2019 20:33 UTC | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock | 100 | $5.96 | $596.00 |
DisclosureSEC source: 0001213900-19-016453 · ownership.xml · nonDerivative · entry 3 Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,539,233 F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 20, 2019 in eleven open market transactions. Read SEC document |
| August 20, 2019 Filed Aug 21, 2019 20:33 UTC | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock | 100 | $5.96 | $596.00 |
DisclosureSEC source: 0001213900-19-016453 · ownership.xml · nonDerivative · entry 2 Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,539,133 F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 20, 2019 in eleven open market transactions. Read SEC document |
| August 20, 2019 Filed Aug 21, 2019 20:33 UTC | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock | 100 | $5.96 | $596.00 |
DisclosureSEC source: 0001213900-19-016453 · ownership.xml · nonDerivative · entry 1 Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,539,033 F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 20, 2019 in eleven open market transactions. Read SEC document |
| August 09, 2019 Filed Aug 12, 2019 21:34 UTC | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock | 1,000 | $6.91 | $6,909.50 |
DisclosureSEC source: 0001213900-19-015380 · ownership.xml · nonDerivative · entry 3 Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,538,933 F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 9, 2019 in two open market transactions. Read SEC document |
| August 09, 2019 Filed Aug 12, 2019 21:34 UTC | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock | 900 | $7.14 | $6,428.79 |
DisclosureSEC source: 0001213900-19-015380 · ownership.xml · nonDerivative · entry 2 Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,537,933 F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 9, 2019 in two open market transactions. Read SEC document |
| August 09, 2019 Filed Aug 12, 2019 21:34 UTC | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock | 100 | $7.20 | $720.00 |
DisclosureSEC source: 0001213900-19-015380 · ownership.xml · nonDerivative · entry 1 Tesi Raymond Joseph · CIK 0001767280 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,537,033 F1 · shares: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 9, 2019 in two open market transactions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.